GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Retained Earnings

KalVista Pharmaceuticals (STU:4XC1) Retained Earnings : €-390.22 Mil (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. KalVista Pharmaceuticals's retained earnings for the quarter that ended in Jan. 2024 was €-390.22 Mil.

KalVista Pharmaceuticals's quarterly retained earnings declined from Jul. 2023 (€-333.03 Mil) to Oct. 2023 (€-375.06 Mil) and declined from Oct. 2023 (€-375.06 Mil) to Jan. 2024 (€-390.22 Mil).

KalVista Pharmaceuticals's annual retained earnings declined from Apr. 2021 (€-140.31 Mil) to Apr. 2022 (€-231.66 Mil) and declined from Apr. 2022 (€-231.66 Mil) to Apr. 2023 (€-312.89 Mil).


KalVista Pharmaceuticals Retained Earnings Historical Data

The historical data trend for KalVista Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Retained Earnings Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -82.30 -111.87 -140.31 -231.66 -312.89

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -293.97 -312.89 -333.03 -375.06 -390.22

KalVista Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


KalVista Pharmaceuticals  (STU:4XC1) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


KalVista Pharmaceuticals (STU:4XC1) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines